What is the frequency of GBS as an AstraZeneca vaccine side effect?

Question

Accepted Answer

Guillain-Barre Syndrome is a Very Rare Side Effect of the AstraZeneca Vaccine

Guillain-Barre Syndrome (GBS) has been identified as a "very rare" side effect associated with the AstraZeneca Covid-19 vaccine, Vaxzevria. This designation means it occurs in fewer than one in 10,000 individuals. The European Medicines Agency (EMA) considers a causal relationship between GBS and the vaccine to be "at least a reasonable possibility."
Reported Cases Worldwide

As of July 31, a total of 833 cases of GBS were reported globally following the administration of approximately 592 million doses of the AstraZeneca Vaxzevria vaccine. The EMA's assessment incorporates these reported instances to inform its classification of the side effect's frequency.
Nature of Guillain-Barre Syndrome

GBS is a disorder involving inflammation of the nerves. It can manifest as temporary paralysis and may lead to difficulties with breathing. In the United States, this rare neurological syndrome affects an estimated 3,000 to 6,000 individuals annually, with most making a full recovery.
Recommended Warning for Vaccine Information

In light of the identification of GBS as a very rare side effect, the EMA has advised that the product information for Vaxzevria should include a warning. This warning is intended to prompt individuals to seek immediate medical attention if they experience symptoms such as weakness and paralysis in their extremities, which could potentially spread to the chest and face.

Reading history

Hide →

This history is cleared when the page is closed.

What is the frequency of GBS as an AstraZeneca vaccine side effect?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends